SCHEMBL992685

SCHEMBL992685

CC(C)N(C(C)C)P(O)NCCC#N

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.32
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1402222 0.77 TSHR (0.30) TSHR
SCHEMBL8603645 0.73 ALDH1A1 (0.30)
SCHEMBL8509214 0.69 TSHR (0.33) TSHR
SCHEMBL40958 0.69
SCHEMBL8558689 0.66
SCHEMBL991911 0.66
SCHEMBL252367 0.65 TSHR (0.30) TSHR
SCHEMBL7262903 0.65 TSHR (0.30) TSHR
SCHEMBL7858703 0.65 TSHR (0.30) TSHR
SCHEMBL634591 0.64 TSHR (0.36) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10131908-B2 5′ phosphate mimics ALNYLAM PHARMACEUTICALS, INC. (US) 2018-11-20 US disclosed
US-20150080457-A1 5' PHOSPHATE MIMICS BANK OF AMERICA, N.A. 2015-03-19 US disclosed
US-8927513-B2 5′ phosphate mimics ALNYLAM PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
US-8278425-B2 N-substituted-aminomethylene bridged bicyclic nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2012-10-02 US disclosed
EP-2170917-B1 N-SUBSTITUTED-AMINOMETHYLENE BRIDGED BICYCLIC NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS INC (US) 2012-06-27 EP disclosed
US-20120157511-A1 5' PHOSPHATE MIMICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-06-21 US disclosed
WO-2011005860-A2 5' PHOSPHATE MIMICS ALNYLAM PHARMACEUTICALS, INC. (US) 2011-01-13 WO disclosed
US-20100249211-A1 N-Substituted-Aminomethylene Bridged Bicyclic Nucleic Acid Analogs IONIS PHARMACEUTICALS, INC. 2010-09-30 US disclosed
EP-2170917-A2 N-SUBSTITUTED-AMINOMETHYLENE BRIDGED BICYCLIC NUCLEIC ACID ANALOGS Isis Pharmaceuticals, Inc. (US) 2010-04-07 EP disclosed
WO-2008150729-A2 N-SUBSTITUTED-AMINOMETHYLENE BRIDGED BICYCLIC NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS, INC. (US) 2008-12-11 WO disclosed
EP-0686150-B1 Process for the preparation of C-nucleosides and C-nucleoside analogues, new C-nucleosides and C-nucleoside analogues and their use MAX DELBRUECK CENTRUM (DE) 1998-05-20 EP disclosed
EP-0686150-A1 Process for the preparation of C-nucleosides and C-nucleoside analogues, new C-nucleosides and C-nucleoside analogues and their use MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 1995-12-13 EP disclosed
WO-1994019327-A1 NUCLEOSIDES, THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS AND AS BUILDING BLOCKS OF SYNTHETIC OLIGONUCLEOTIDES Max-Delbrück-Centrum für Molekulare Medizin (DE) 1994-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157511-A1 5' PHOSPHATE MIMICS NSUN2, RNGTT, RNMT THRB 2317/4885TSHR 3336/4885
US-20150080457-A1 5' PHOSPHATE MIMICS NSUN2, RNGTT, RNMT THRB 2330/4885TSHR 3344/4885
US-10131908-B2 5′ phosphate mimics NSUN2, RNGTT, RNMT THRB 2281/4885TSHR 3339/4885
US-20100249211-A1 N-Substituted-Aminomethylene Bridged Bicyclic Nucleic Acid Analogs NSUN2, RNMT, NSUN3 THRB 4100/4885TSHR 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.